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Plasma Proteome Profiling to detect and avoid
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Abstract
Plasma and serum are rich sources of information regarding an
individual’s health state, and protein tests inform medical decision
making. Despite major investments, few new biomarkers have
reached the clinic. Mass spectrometry (MS)-based proteomics now
allows highly specific and quantitative readout of the plasma
proteome. Here, we employ Plasma Proteome Profiling to define
quality marker panels to assess plasma samples and the likelihood
that suggested biomarkers are instead artifacts related to sample
handling and processing. We acquire deep reference proteomes of
erythrocytes, platelets, plasma, and whole blood of 20 individuals
(> 6,000 proteins), and compare serum and plasma proteomes.
Based on spike-in experiments, we determine sample quality-asso-
ciated proteins, many of which have been reported as biomarker
candidates as revealed by a comprehensive literature survey. We
provide sample preparation guidelines and an online resource
(www.plasmaproteomeprofiling.org) to assess overall sample-
related bias in clinical studies and to prevent costly miss-assign-
ment of biomarker candidates.
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Introduction
Protein levels determined in blood-based laboratory tests can be
useful proxies of diseases. These biomarkers assess normal physio-
logical status, pathogenic processes, or a response to an exposure or
intervention (FDA-NIH:Biomarker-Working-Group, 2016). Proteins
and enzymes constitute the largest proportion of laboratory tests,
reflecting the importance of the plasma proteome in clinical diag-
nostics (Geyer et al, 2017). Typical protein biomarkers such as the
enzymes aspartate aminotransferase (ASAT) and alanine amino-
transferase (ALAT) for the diagnosis of liver diseases or cardiac
troponins indicating myocardial necrosis are used routinely in clini-
cal decision making. Enzymatic activity or antibody-based labora-
tory tests are performed in high-throughput and at relatively low
costs, as the standard of health care. However, specific biomarkers
are only available for a very limited number of conditions and most
have been introduced decades ago (Anderson et al, 2013). There is
thus a critical need to make the biomarker discovery process more
efficient.
Protein-binder assays quantifying many plasma proteins in paral-
lel have become available (Gold et al, 2010; Assarsson et al, 2014),
resulting in large-scale biomarker mining efforts (Ganz et al, 2016;
Herder et al, 2018; Sun et al, 2018). Orthogonal to those technolo-
gies, mass spectrometry (MS)-based proteomics has become increas-
ingly powerful in all domains of protein research (Aebersold &
Mann, 2003, 2016; Munoz & Heck, 2014). MS measures the mass
and fragmentation spectra of tryptic peptides derived from the
sample with very high accuracy. Because these peptide and fragment
masses are unique, MS-based proteomics is inherently specific, which
can be an advantage over enzyme tests and immunoassays (Wild,
2013). Within its limit of detection, MS-based proteomics can analyze
all proteins in a system and is unbiased and hypothesis-free in this
sense.
The proteomic community has developed guidelines for the
development, specificity, and potential clinical application of
biomarkers. These discuss quality standards and emphasize the
importance of selecting cohorts that are appropriate in size, thus
ensuring the statistical significance of potential findings (Mischak
et al, 2010; Surinova et al, 2011; Skates et al, 2013; Hoofnagle et al,
2016; Geyer et al, 2017). That being said, there are no systematic
procedures in place to assess the proteome-wide effects of pre-analy-
tical handling of blood-based samples. Considering that plasma
samples are often collected during daily clinical routine and variably
processed, sample collection and processing clearly have the poten-
tial to negatively influence clinical studies, making it difficult to
uncover true biomarkers, while potentially contributing incorrect
ones. Especially in case–control studies, any difference in the
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collection and processing of samples may result in systematic bias.
So far, relatively little attention has been paid to this crucial aspect
on a proteome-wide scale and these studies mainly investigate pre-
analytical effects (Rai et al, 2005; Timms et al, 2007; Schrohl et al,
2008; Qundos et al, 2013; Hassis et al, 2015).
Recently, we developed “Plasma Proteome Profiling”, an auto-
mated MS-based pipeline for high-throughput screening of plasma
samples (Geyer et al, 2016a). In this article, we apply this technol-
ogy to systematically assess the quality of individual samples and
clinical studies with the aim to identify generally applicable qual-
ity marker panels. Blood collection and subsequent errors in
preparation are likely sources of plasma contamination. To
address this issue, we construct proteomic catalogs of contaminat-
ing cell types as well as proteomic changes that may be induced
during processing. This results in three panels of contaminating
proteins, recommendations for assessing the quality of plasma
samples and for consistent sample processing. We develop an
online tool for biomarker studies and test the applicability of the
panels on a recent investigation on the effects of weight loss on
the plasma proteome (Geyer et al, 2016b). A comprehensive litera-
ture review of plasma proteome studies highlights that about half
of them potentially suffer from limitations related to sample
processing.
Results
Erythrocyte and platelet proteins in the plasma proteome
During the development of our Plasma Proteome Profiling pipeline
and its optimization for high-throughput screening of human
cohorts (Geyer et al, 2016a), we repeatedly observed proteins that
tended to emerge as groups of statistically significant outliers but
appeared to be independent of the particular study. We hypothe-
sized that they reflected sample quality issues. Manual and bioinfor-
matic inspection revealed three classes of origin: erythrocytes,
platelets, and the blood coagulation system. Consequently, we
designed experiments to systematically characterize these main
quality issues of the plasma proteome.
First, we acquired reference proteomes of erythrocytes and plate-
lets, which are by far the most abundant cellular components
(5 × 106 and 3 × 105 cells per ll). We harvested these cellular
components from 10 healthy females and 10 males to obtain repre-
sentative erythrocytes, platelets, and pure (platelet-free) plasma and
further collected platelet-rich plasma and whole blood (Fig 1A; see
Materials and Methods). Cell counting confirmed the purity of the
samples (Table EV1). All five blood fractions were separately
prepared for each individual by our automated proteomic sample
preparation pipeline, followed by liquid chromatography coupled to
high-resolution mass spectrometry (LC-MS/MS). To create reference
proteomes, we generated a very deep library from pooled samples
by analyzing extensively pre-fractionated peptides (Kulak et al,
2017; see Materials and Methods). A total of 6,130 different proteins
were identified from 61,654 sequence-unique peptides (Fig 1B and
C). The platelet proteome was the most extensive (5,793 proteins),
whereas we detected 2,069 proteins in erythrocytes, 1,682 in
platelet-rich plasma, and 912 in platelet-free plasma. The compar-
ison of platelet-rich plasma to platelet-free plasma (84% additional
proteins) demonstrates the extent of proteins that can be introduced
by platelets.
Next, we investigated purified samples for all 20 study partici-
pants individually. The average numbers of identified proteins and
peptides were very consistent in all individuals (Appendix Fig S1).
To construct panels of easily detectable and robust quality mark-
ers, we calculated the average protein intensities and the coeffi-
cient of variation (CV) across the study participants. As a
prerequisite, we required that the proteins should be substantially
more abundant in erythrocytes as well as platelets rather than in
plasma. According to these criteria, we selected the 30 most abun-
dant proteins with CVs below 30% and at least a 10-fold higher
expression level in the contaminating cell type than in plasma
(Fig 1D and E). NIF3-like protein 1 (NIF3L1), a low-abundance
erythrocyte-specific protein, was excluded, because it was incon-
sistently identified as was the platelet-bound coagulation factor
F13A1, whose function makes it an unsuitable platelet marker.
The remaining proteins represent our cellular quality marker
panels (Table EV2). They overlap by just two proteins (actin/ACTB
and glyceraldehyde-3-phosphate dehydrogenase/GAPDH), and
their quantities were not correlated with each other (Appendix Fig
S2). Thus, they are specific and independent indicators for the
origin of plasma quality.
Comparing median expression values of proteins shared between
the blood components revealed that plasma proteins do correlate
with whole blood (Pearson’s correlation coefficient R = 0.43), as
expected. In contrast, there was no correlation between the platelet,
erythrocyte, and plasma proteomes (Appendix Fig S2). This indi-
cates that the levels of cellular proteins in plasma are not a constant
fraction of those in the cellular proteomes. The platelet panel was
enriched in platelet-rich plasma compared to normal (platelet-free)
plasma. Both panels are de-enriched in pure plasma compared to
whole blood, however, this effected the erythrocyte panel even
more strongly, because centrifugation removes erythrocytes more
efficiently than platelets. A histogram of both panels over the abun-
dance range visualizes their distribution in the different blood
compartments (Appendix Fig S2). Erythrocytes are 10-fold more
abundant and fourfold larger than platelets, and indeed, the corre-
sponding panel proteins have a 42-fold difference in whole blood.
In plasma, however, their ratio was nearly one to one, again
pinpointing a more efficient removal of erythrocytes than of plate-
lets in standard sample preparation. The fact that several proteins
of both panels were still detectable in pure plasma indicates a base-
line level of contaminants due to imperfect de-enrichment or the life
cycle of these cells. The four most abundant erythrocyte proteins,
HBA1, HBB, CA1, and HBD, were present in pure plasma of almost
all individuals, whereas lower abundant proteins were only sporadi-
cally identified. In contrast, platelet proteins were quantified over a
larger abundance range and some of them were found in every indi-
vidual.
In addition to the sum of panel protein abundances, we calcu-
lated their correlation to the standard reference panel defined by the
20 participants to several hundred plasma samples of a previous
study (Geyer et al, 2016b). A distinct contamination of erythrocyte
proteins seems to be a part of the plasma proteome as the erythro-
cyte panel has in general a relatively high correlation between the
reference cohort erythrocyte levels and the plasma samples in the
above-mentioned study. In contrast, in many plasma samples there
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was no correlation detectable between the reference cohort platelet
levels and the plasma samples in the study. In practice, a correla-
tion > 0.5 indicated that the proteins are present as a result of
contamination (Appendix Fig S3A–C). Note that an apparent
contaminant protein could still be applied as a biomarker—
however, in this case its abundance value should be different from
the pattern in the reference quality panel.
Serial dilution experiments validate the erythrocyte and platelet
quality marker panels
To determine whether the two protein panels correctly quantify
contamination in plasma, we generated four pools of erythrocytes
and platelets from five study participants at a time. These pools were
diluted in nine steps into platelet-free plasma for a total range of 107,
followed by cell counting and proteomic analysis (Fig 2A). This
resulted in an expected decrease in the cellular proteome ratio to
plasma (Fig 2B and C). All but two of the panel proteins were consis-
tently quantified over the dilution range. As the protein within each
panel has the same origin, we defined a single variable for each cell
type by summing their intensities and dividing by the summed inten-
sities of all quantified plasma proteins. This yielded two remarkably
robust “contamination indices” that turned out to be linear with
respect to the cell numbers determined by cell cytometry
(Table EV3; R = 0.98 and 0.99, Fig 2D and E). Spiked-in
contaminations of 1:100 could readily be detected, which corre-
sponds to a concentration of 70,000 erythrocytes or 30,000 platelets
per ll plasma.
Quality marker panel for blood coagulation
In addition to contamination due to cellular constituents, partial and
variable coagulation could contribute to systematic bias in
biomarker studies. Indeed, we had found coagulation-related
proteins to be connected to sample handling from finger pricks
while developing our plasma proteomics pipeline (Geyer et al,
2016a). In clinical practice, an anticoagulant is pre-added to
commercially available containers so that it is combined with blood
upon withdrawal. Prompt inversion mixes the anticoagulant with
the blood, yielding pure plasma after centrifugation (Fig 3A). Any
delay in adding or mixing could cause partial coagulation—in the
extreme case of missing anticoagulant and waiting for 30 min, one
would obtain serum instead of plasma.
To generate a panel for assessing blood coagulation, we systemati-
cally compared 72 plasma vs. 72 serum samples (four individuals, 18
aliquots). From a total of 2,099 quantified proteins, 299 were signifi-
cantly altered (Fig 3B). The most significantly de-enriched proteins
after clotting were typical constituents of the coagulation cascade
such as fibrinogen chains alpha (FGA), beta (FGB), and gamma
(FGG) (P < 10130, > 40-fold), whereas the platelet-associated
A
B C D E
Figure 1. Identification of blood cell markers.
A Study outline and proteomic workflow. Erythrocytes, thrombocytes, platelet-rich, and platelet-free plasma were generated from 10 healthy female and male
individuals by differential centrifugation and successive purification steps. To generate reference proteomes for each of the blood compartments, the respective
protein samples of the 20 study participates were digested to peptides.
B, C Proteins (B) and peptides (C) identified for platelets, erythrocytes, platelet-rich, and platelet-free plasma.
D, E Selection of the most suitable quality marker proteins for (D) platelet contamination (blue dots) and (E) erythrocyte contamination (red dots) based on their
abundance, the platelet/erythrocyte-to-plasma ratio, and the coefficient of variation. Proteins that were only detected in platelets or erythrocytes, but not in
plasma are aligned on the right side of the graph.
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coagulation factor F13A1 and antithrombin-III (SERPINC1) decreased
by more than half. Interestingly, the strongest elevated proteins in
serum were highly abundant platelet proteins: platelet basic protein
(PPBP), platelet glycoprotein Ib alpha chain (GP1BA), throm-
bospondin 1 (THBS1), and platelet glycoprotein V (GP5) (P < 1010;
twofold to fivefold increase). In total, 208 proteins increased and 91
decreased due to coagulation. The former set of proteins, which have
higher levels in serum than in plasma, were also quantitatively
enriched with high-abundant platelet proteins (P < 105; median
rank 699 of 3,150 proteins), indicating coagulation-induced activa-
tion of platelets.
To define a robust panel of quality markers for the extent of
coagulation, we first selected the 30 most significantly altered
proteins between serum and plasma. Although not among the top
30, we added the platelet factor 4 variant 1 (PF4v1; P < 1011, 2.2-
fold up in serum), because it was an excellent indicator of
coagulation in our studies and has already been reported in the
context of pre-analytical variation (Timms et al, 2007).
In contrast to the erythrocyte and platelet panels, proteins of the
coagulation panel increase or decrease due to blood clotting and the
fold changes vary strongly between them. Because fold changes are
greatest for the decreasing proteins, we calculated the coagulation
marker ratio only from them (sum of all plasma proteins divided by
sum of plasma-elevated coagulation proteins). This ratio was very
robust when comparing serum and plasma, clearly separating them
with median ratios of 9 and 120 for these distinct sample types
(Fig 3C). Of the coagulation marker panel, only F13A1, PPBP, and
THBS1 were in common with the platelet panel and none with the
erythrocyte panels (Fig 3D). The low overlap observed for the three
quality marker panels should make them highly specific tools to
elucidate the presence and origin of sample-related bias.
Application of the quality marker panels to a biomarker study
The above-defined marker panels can assess sample-related issues
at three levels: the quality of each sample in a clinical cohort, poten-
tial systematic bias in the entire study, and the likelihood that indi-
vidual biomarker candidates belong to the contaminant proteomes.
We recently investigated changes in the plasma proteome upon
weight loss (Geyer et al, 2016a,b). Briefly, caloric restriction in 52
individuals for 2 months was followed by weight maintenance for
1 year. Plasma Proteome Profiling of seven longitudinal samples
revealed significant changes in the profile of apolipoproteins, a
decrease in inflammatory proteins and markers correlating with
insulin sensitivity. Given that protein abundance changes of < 20%
were often highly significant, we expected that overall sample qual-
ity was high, making this study suitable for testing the practical
applicability of the quality marker panels.
First, we assessed the quality of each sample separately by calcu-
lating the three contamination indices and plotting their distribution
in the total of 318 measurements. For each index, we initially
defined potentially contaminated samples as those with a value
more than two standard deviations above the mean (red lines in
Fig 4A). This flagged 12 samples, six with platelet contamination,
one with increased erythrocyte levels, and five with signs of partial
coagulation. Resolving the three quality marker panels to the levels
of individual proteins resulted in almost perfectly parallel trajecto-
ries (Appendix Fig S4A–C). Accordingly, the correlations to the
reference quality marker panels were substantial (R > 0.77). Over-
all, the variation of the contamination indices was highest for the
platelets also visible by a contamination index difference (max/min
ratio) of a factor 182 between the least and the most contaminated
sample, followed by erythrocytes (max/min 23), and lowest for
coagulation (max/min 5). The platelet proteins talin-1 (TLN1),
myosin-9 (MYH9), and alpha-actinin-1 (ACTN1) had the largest
variations, all with maximal changes > 5,000-fold. Catalase (CAT),
carbonic anhydrase 1 and 2 (CA1, CA2) from the erythrocyte index
varied maximally by more than 500-fold. The three fibrinogens in
the coagulation panel changed by up to 20-fold, indicating that only
partial coagulation events took place (Fig 4A).
Note that evaluating individual sample quality based on the stan-
dard deviation of all samples, as done here, has the benefit of being
independent of the specific proteomic method used to measure
protein amounts. However, this requires that most samples have
A
B D
C E
Figure 2. Spike-in of erythrocyte and platelet fractions into pure plasma.
A Dilution and analysis scheme.
B, C Protein intensities were Z-scored across the dilution series (B) for the 29
quality markers of the erythrocyte panel and (C) for the 29 markers of
the platelet panel as a function of their spike-in proportion to plasma.
Whiskers indicate 10–90 percentiles, and horizontal lines denote the
mean.
D Correlation of erythrocyte count to the “contamination index” for the
erythrocyte marker panel.
E Correlation of platelet count to contamination index for the platelet
marker panel.
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low levels of contamination, so that outliers of the statistical distri-
bution are clearly apparent. If this is not the case, we propose using
general, study-independent cutoff values to differentiate between
samples of high and poor quality in such studies.
To assess potential systematic bias for groups of samples such as
cases and controls or different time points, we applied a t-test based
volcano plot. Most of the significantly upregulated proteins at time
point 4 were members of the platelet panel (Fig 4B). With this infor-
mation in hand, we contacted our collaboration partners, who
tracked down the platelet contamination to a switch of the blood-
taking equipment due to low supplies.
In practice, such sample issues will occasionally happen in a clinical
study, and our quality marker panels would allow elimination of the
affected samples. However, if contaminating proteins can reliably be
distinguished from relevant biomarker candidates, the data could still
be used. In our example, six of the eight significant outliers were from
the platelet panel, and the other two proteins—GP1BA and NRP1—
could still be of interest. To investigate this further, we inspected the
global correlation map of all proteins, time points, and participants
(Albrechtsen et al, 2018). In this hierarchical clustering analysis,
proteins that are co-regulated have a high correlation to each other and
appear in groups, visualized as red patches (Fig 4C). Here, the platelet
cluster was the second largest one with 38 proteins (R = 0.69). All
quantified platelet panel proteins were in this cluster, as was GP1BA,
flagging them as likely contaminants (Fig 4C and inset). Interestingly,
NRP1, a receptor involved in angiogenesis, did not group with the
platelet proteins, suggesting a potential biological role. This is
supported by the fact that NRP1 was significantly regulated over all
time points compared to the baseline, in contrast to the platelet cluster
proteins.
The other two quality marker panels are also readily apparent in
the global correlation map. Ten members of the erythrocyte panel
cluster tightly as do the three fibrinogen chains (Appendix Fig S5).
However, in this study the fibrinogens group with proteins involved
in low-grade inflammation, reduction of which was one of the main
findings of our study (Appendix Fig S5). In contrast, the coagulation
marker PF4v1, which is also a highly abundant protein in platelets,
clustered in the platelet group in this analysis, indicating that it
varied as a result of sample preparation.
To make the above-described analysis readily available, we
created an online platform at www.plasmaproteomeprofiling.org. It
provides a toolbox for the interactive assessment of the quality of
plasma proteomic data. Lists of protein abundances from MaxQuant
search result tables or the template (Table EV4) can be uploaded by
a simple drag and drop system. The system automatically generates
the three contamination index values as shown in Fig 4A. If the user
indicates cases and controls, the data set will be analyzed for
systematic bias as visualized in a volcano plot (Fig 4B). The global
correlation map is also displayed with the clusters of the quality
marker panels (Fig 4C). The website is designed in the Dash data
visualization framework, which allows further interactive analysis
of the data (see Materials and Methods). Potential biomarker candi-
dates in the volcano plot can be selected and displayed in the global
correlation map to check whether the protein falls into or near one
of the quality marker clusters.
Revisiting results of published biomarker studies
Having examined one study in detail, we set out to survey the
extent to which quality marker proteins are reported as biomarker
candidates in the literature. To this end, we performed a compre-
hensive PubMed search requiring the terms ‘proteomics‘, ‘pro-
teome‘, ‘plasma OR serum‘, ‘biomarker‘ and ‘mass spectrometry‘
spanning the time frame from 2002 to April 2018. We excluded
review papers, purely technological publications without
biomarker candidates, animal studies, and publications without
proteins as qualitative or quantitative variables. From the resulting
210 publications, we manually extracted the lists of the biomarker
candidates that were reported as “significantly altered proteins” by
the authors. Gene and protein names were mapped to the corre-
sponding protein identifiers in our reference panels and analyzed
for their frequencies.
A B C D
Figure 3. Quality marker panel for blood coagulation.
A Preparation of plasma and serum samples. EDTA was used as anticoagulation agent, and incubation and centrifugation values are indicated.
B Volcano plot comparing 72 plasma vs. 72 serum proteomes. Proteins highlighted in yellow were chosen according to their P-value as markers for coagulation. Only
the plasma-enriched proteins (compared to serum) were used in the calculation of the coagulation contamination index.
C Ratio of the summed intensities of all plasma or serum proteins to the sum of the plasma-enriched panel proteins is plotted for all samples. Whiskers indicate the
10–90 percentile, and horizontal lines denote the mean.
D Overlap of the three quality marker panels.
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Remarkably, 113 studies (54%) reported at least one potential qual-
ity marker as a biomarker candidate or as a statistically significant
association (Fig 4D). As the total quality marker panel consists of 84
proteins and the median number of candidates per clinical study was
seven, a certain overlap is not entirely unexpected. However, the
candidates in question almost always were near the top of most abun-
dant proteins of the quality marker panels, making it highly likely that
they are indeed contaminants. Furthermore, while an individual
protein could still be a genuine biomarker candidate, the fact that 22
studies (11%) reported two of them, and a further 23 studies (11%)
three or more, again makes quality issues the likely explanation.
The majority of these studies reported proteins as potential
biomarkers or as significant outliers of the coagulation panel, followed
by the erythrocyte and platelet panels (Fig 4E). The most frequent one
was clusterin (CLU; 27 times), followed by the fibrinogens (alpha, beta,
and gamma; 22, 10, and 15 times), prothrombin (F2; 17 times), kinino-
gen (KNG1; 15 times), antithrombin-III (SERPINC1; 13 times), and
platelet basic protein (PPBP; 10 times). It is worth noting that proteins
related to erythrocyte leakage may falsely be taken to indicate activa-
tion of oxidative pathways. For example, the hemoglobin subunits
(e.g. HBA1, HBB, and HBD, listed 1, 6, and 1 time), carbonic anhy-
drases (CA1 and CA2, 6 and 6 times), fructose-bisphosphate aldolase
(ALDOA, 5 times), peroxiredoxin 2 (PRDX2, 3 times), and superoxide
dismutase (SOD1; 2 times) are annotated with keywords linked to
oxidation. To illustrate this, a recent publication connected plasma
proteome alterations in type 1 diabetes to oxidative stress. This may be
a spurious link because the reported proteins were mostly members of
the erythrocyte quality marker panel (Liu et al, 2018). Although
platelet panel proteins are not prominent in the biomarker literature
yet, we expect that they—along with lower abundant erythrocyte-
specific proteins—will play an increasing role as technological progress
enables higher plasma proteome coverage. We caution that platelet
proteins already found in the biomarker literature such as PPBP,
THBS1, and PF4 are often linked to coagulation events.
Recommendations for future proteomic studies
Based on our experience with the above-defined three quality
marker panels (Table EV2) and analysis of thousands of plasma
proteomes, we devised a general guideline for minimizing and
detecting biases related to sample taking and processing (Table 1).
To further document the influence of common variables in the
blood-taking process, we invited 10 healthy individuals and
collected blood in 10 different blood sampling tubes. In this experi-
ment, we systematically varied the type of plasma/serum, the blood
specimen tubes (with or without gel), and the deposition of blood
into the sampling tube (vacuum vs. pull system).
The most prominent differences were again between serum and
plasma (Fig 3B; Appendix Fig S6). Apart from this, we found that
contaminations with high-abundant erythrocyte-specific proteins
appeared in several comparisons. Serum and EDTA plasma both had
significantly higher levels than lithium heparin and citrate plasma
(Appendix Fig S6A–F). Moreover, vacuum sampling can have an
influence on erythrocyte-specific protein levels for some tubes. For
instance, we found significantly increased levels of HBA1 and HBB
in lithium heparin plasma tubes after vacuum sampling compared to
a pull system, but not in the same comparison when using serum
tubes (Appendix Fig S7A–D). Furthermore, erythrocyte-specific
proteins were significantly increased in lithium heparin pull tubes
(more than twofold), which contain a gel plug compared to pull
tubes without a gel plug (Appendix Fig S8A–D). In contrast, there
were no differences between serum tubes with and without gel.
These findings illustrate how even seemingly minor changes in
blood-taking equipment can result in statistically significant dif-
ferences of protein levels, which could confound biomarker studies.
They also highlight the value of unbiased, system-wide investigation
of the blood proteome and our quality marker panels.
We also found that the procedure of sampling the plasma from the
tubes has a prominent effect on platelet contamination (Appendix Figs
S9 and S10). Thus, we recommend not to collect the lowest layer of
the plasma above the platelet bed after centrifugation. Furthermore,
any delay from centrifugation to plasma harvest has the potential to
induce platelet protein contamination. These factors mainly influence
the platelet rather than the erythrocyte contamination index, indicating
that proteins from the platelet proteome are the most likely cause of
erroneous assignment of biomarker candidates.
Discussion
Blood plasma remains the predominant biological matrix to assess
health and disease in clinical settings. Around the world, every day
hundreds of thousands of samples are analyzed to determine the
levels of individual proteins. Likewise, blood plasma is directly or
indirectly assessed in most clinical trials. Protein levels in plasma
can readily be affected by cellular contamination or handling-related
issues, and in clinical practice, this is partially addressed by simple
tests such as those for hemoglobin contamination. However, these
tests are not systematic or quantitative and they can only be used to
exclude clearly contaminated samples.
Because of its high specificity and unbiased nature, MS-based
proteomics is ideally suited to characterize the quality of blood
plasma and it requires < 1 ll of material. So far, research on sample
quality involving MS has mainly been restricted to the stability of
internal standards in targeted assays and has rarely addressed over-
all sample quality (Schrohl et al, 2008; Hassis et al, 2015; Hoofnagle
et al, 2016). Employing our Plasma Proteome Profiling pipeline to
various clinical studies suggested that platelets, erythrocytes, and
coagulation are by far the most important causes of plasma quality
issues. We acquired very deep reference proteomes for these cell
types and blood compartments, which we provide to the community
to evaluate the possible origin of proteins emerging from biomarker
studies. We defined three panels of about 30 proteins each that can
serve as contamination indices (Table EV2). Using the example of a
longitudinal Plasma Proteome Profiling study of weight loss and our
online resource, we illustrated how the contamination indices can
flag individual suspect samples and systematic biases. Furthermore,
correlation analysis reveals whether potential biomarkers emerging
from a given study are likely to be associated with quality-related
proteome changes instead. Conversely, this procedure can “rescue”
genuine biomarker candidates that are part of the quality marker
proteomes. As an example, fibrinogens, a member of the coagula-
tion quality marker panel, can also change during an inflammatory
condition and might be correlated with classical inflammation mark-
ers such as CRP. In certain diseases, the entire set of proteins of a
quality marker panel can be altered. For example, increased platelet
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levels—thrombocythemia—can have a variety of causes ranging
from chronic inflammation to myeloproliferative diseases. Likewise,
increased concentration of erythrocyte-specific proteins can be
caused by hemolytic diseases such as in autoimmunity. While these
cases are not the usual reasons why a quality marker panel is
altered, they need to be considered when judging the analytical
validity of a plasma measurement.
The clinical potential of the plasma proteome has long been
realized and is also emphasized by the fact that more than 50
FDA-approved biomarkers can be quantified even in relatively
shallow proteomic measurements of plasma (Geyer et al, 2016a).
If there are as many new biomarkers among the less abundant
proteins, there should be a diagnostic treasure trove still to be
discovered (Geyer et al, 2017). Millions of plasma samples are
stored in biobanks worldwide, representing an immense untapped
resource that could be analyzed by MS-based proteomics or large-
scale affinity-based methods. Despite initial enthusiasm and
community efforts such as the Human Proteome Organization’s
plasma proteomic initiative (Omenn et al, 2005; Schwenk et al,
2017), few if any new protein biomarkers have entered the clinic
in recent decades. This is probably at least partially due to techno-
logical limitations to characterize the vast dynamic range of the
plasma proteome, which in turn has led to underpowered study
designs (Geyer et al, 2017). While many of these challenges are
already being addressed, we suspect that problems with sample qual-
ity represent another important reason for the paucity of new
biomarkers and, even more seriously, for incorrect biomarkers being
used. Examining our own data as well as the scientific literature, we
here show that sample quality issues indeed have an impact on
reported results. Nearly half of the reviewed studies reported at least
one potential biomarker that is in our quality marker panels, and
many had two or more, making sample contamination very likely.
While coagulation-related issues are currently most prominent,
increasing depth of plasma proteome coverage may replace platelet
contamination as the most important source of error in the future. A
corollary of the very large abundance variation of proteins introduced
by quality issues is that it should further discourage pooling of
samples. While this increases throughput, even a single contaminated
sample can readily skew an entire batch.
Systematic bias introduced by imperfect sample handling or
processing may lead to reporting incorrect biomarkers. Conversely,
randomly distributed samples with poor quality will diminish over-
all statistical quality and may obscure true biomarker candidates.
The sources of quality issues are different kinds of variations in
the pre-analytical processes, and we found platelet contamination
during plasma harvesting to be one of the main culprits. Among the
few previous studies, Hassis et al (2015) investigated different
sample handling errors and concluded that only extreme conditions,
such as delay in sample storage for 4 days, substantially changed
the plasma proteome. However, proceeding with such extreme cases
is rare, and quality issues are much more likely to originate from
recontamination with whole blood after centrifugation during the
plasma harvest or post-centrifugation times and resuspension of
platelets, for instance. The comparison of 10 different blood
sampling tubes showed that even seemingly minor differences in
Table 1. Practical considerations to minimize systematic bias.
General instructions
Avoid pooling of samples
Use plasma or serum exclusively, not a combination
Sample collection
Standardize blood collection and pre-analytical procedures (preferably
same person collecting blood, centrifuge, sampling container, storage
temperature, and time)
Centrifuge blood to generate plasma immediately
Centrifuge according to manufacturer’s instruction
Harvest plasma immediately after centrifugation
Harvest the plasma starting from the top of the container and pool it
before aliquotting
Discard the last 500 ll of plasma to avoid contamination with platelets or
use a second centrifugation step to generate platelet-poor plasma
Freeze samples immediately after harvesting
Principal assessment of study sample quality
When working with a new batch of samples from collaborators: run at
least 10 test samples of each study group by mass spectrometry
Use quality marker panels to check for any indication of contamination
Main study
Continuously assess quality during the project to detect and avoid
systematic bias (pre-analytics, mass spectrometric analyses)
Overall quality: report the number of contaminated samples
Systematic bias: report potential systematic bias
Check whether biomarker candidates are contained in the quality marker
panels
Identification of several quality markers as biomarker candidates may be
indicative of a study vector
If a quality marker is among the biomarker candidates, thorough validation
is required
◀ Figure 4. Quality marker panels in a weight loss study and literature study.A Assessment of individual sample quality with respect to the three contamination indices using the online tool at www.plasmaproteomeprofiling.org. Samples with
indices that are more than two standard deviations from the mean (horizontal red lines) are flagged as potentially contaminated (red bars and sample numbers).
B Volcano plot of the proteome comparison of time point 1 vs. 4. Proteins of the platelet panel are highlighted in blue and two additional significantly regulated
proteins in red.
C Global correlation map on the left with an inset of the platelet cluster on the right. The two significant outliers of the volcano plot in (B) are marked in red. Platelet
panel proteins are highlighted in blue in the inset. Red patches in the global correlation map indicate positive and blue patches negative correlations.
D Literature analysis of 210 publications using MS-based plasma proteomics to identify new biomarkers. The number of quality markers reported as biomarker
candidates in these studies is indicated.
E Distribution of the reported quality markers according to the three types of likely contaminations. The distribution is shown across studies that report one, two, or
three proteins of the same quality marker panel.
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the sample handling devices like a pull vs. a vacuum deposition
system can have a statistically significant effect on the measured
proteome. Therefore, we want to stress the importance of strictly
following standard operating procedures. We here provide general
considerations for minimizing sample-related issues, ranging from
immediate harvest of the plasma after centrifugation to discarding
the lowest layer of plasma to avoid recontamination with platelets
(Table 1). These recommendations update and extend general
good laboratory practices as well as HUPO guidelines (Omenn
et al, 2005; Rai et al, 2005). We also advocate that plasma
samples are quality-checked by MS-based proteomics, at least for
a representative subset. This is especially important for clinical
studies but also for targeted single-analyte measurements, which
by their nature are blind to the overall composition of the sample.
Although it would be possible to determine contamination indices
by multiplexed affinity-based methods, we recommend MS for
this purpose because of its very high specificity and its unbiased
nature. Furthermore, the proteomic depth needed to assess the
quality is easily achievable even in rapid and economical
measurements.
The concepts and methods put forward in this study could read-
ily be adapted to other body fluids such as urine, saliva, or cere-
brospinal fluid. This would require developing the appropriate
contamination indices. Furthermore, the three quality marker cate-
gories are the largest but not the only ones. For instance, we imag-
ine that similar experiments can be performed to gauge the effect of
storage duration and temperature on the plasma proteome as it
influences MS-based proteomics.
In conclusion, sample-related quality issues are clearly a concern
for biomarker studies. However, we show here that they can be
addressed rigorously and comprehensively by MS-based proteomics.
As this technology continues to improve in throughput, depth, and
robustness, we envision that it will be employed in routine clinical
practice. Biomarker panels instead of single markers will be
measured by MS-based proteomics as this takes advantage of its
inherently multiplexed nature and allows the characterization of
clinical conditions more comprehensively. These biomarker panels
could routinely be extended with quality marker panels as intro-
duced here, helping to establish biomarker-guided decisions in a
wide variety of clinically important areas.
Materials and Methods
Samples for defining the three quality marker panels
All participants gave written informed consent for their participation
in the Munich Study on Biomarker Reference Values (MyRef), which
is registered under the local ethic number 11-16. All experiments
conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report.
To establish the quality marker panels, whole blood was
harvested by venipuncture of 10 females and 10 males into commer-
cial EDTA-containing sampling containers. The blood was centri-
fuged at 200 g for 10 min, and both the pellet and the supernatant
were kept for further processing steps. The bottom layer of 500 ll
plasma was discarded to avoid contamination of the platelet-rich
plasma fraction with erythrocytes. The pellet was centrifuged at
2,000 g for 15 min, and the top layer containing plasma, the
buffy coat, and 1 ml of erythrocytes were discarded. After adding
4 ml PBS containing 1.6 mg/ml EDTA, the suspension was
centrifuged at 2,000 g for 15 min and the supernatant was
discarded together with 500 ll of the top layer of the erythro-
cytes. This step was repeated, and the pure erythrocyte fraction
was harvested. We centrifuged the supernatant from the first
centrifugation step containing plasma and platelets a second time
at 200 g for 10 min and harvested the supernatant, which consti-
tutes the platelet-rich plasma. This step was repeated, and we
collected the supernatant and the platelet after centrifugation at
2,000 g for 15 min. The supernatant was centrifuged a second
time at 2,000 g for 15 min to harvest platelet-free plasma by
sampling only top layer of the supernatant, but discarding the
bottom layer of 500 ll. The platelets were washed twice by
adding 4 ml PBS containing 1.6 mg/ml EDTA and centrifugation
at 2,000 g for 15 min. The supernatant was discarded, and the
pure platelet fraction was harvested.
For the serum and plasma comparison, blood samples from two
females and two males were split into 18 samples each and serum
and plasma were harvested after centrifugation at 2,000 g for
15 min.
To investigate the effects of different blood sampling devices on
the blood plasma proteome, we invited 10 healthy individuals (five
female and five males) and collected blood in the 10 different blood
sampling devices (Table EV5). After collecting whole blood, it was
incubated at room temperature for 30 min to allow coagulation in
the serum tubes. The plasma tubes were also stored at room temper-
ature for the same time, and the different tubes were centrifuged
together. Afterward, 0.5 ml of plasma or serum was sampled from
the top of the tubes.
To evaluate the platelet contamination in different layers of
plasma after centrifugation, blood was collected in two different 9-
ml S-Monovette EDTA-containing sampling containers (Sarstedt).
The blood of one container was transferred to a 15-ml centrifugation
tube without separation gel. Both containers were centrifuged at
2,000 g for 15 min. Plasma was harvested in nine volume fractions
starting from the top layer in 500 ll steps to the top of the buffy
coat. The buffy coat itself was not touched, and a small amount of
plasma (~200 ll) remained on top.
High-abundant protein depletion for building a matching library
We created a matching library and applied a consecutive deple-
tion strategy, in which the top 6 and top 14 most abundant
plasma proteins were depleted by using a combination of two
immunodepletion kits, as described in ref. Geyer et al (2016a).
Briefly, the Agilent Multiple Affinity Removal Spin Cartridge was
used for the depletion of the top six highest abundant proteins
(albumin, IgG, IgA, antitrypsin, transferrin, and haptoglobin),
followed by Seppro Human 14 Sigma immunodepletion for the
14 highest abundant proteins (albumin, IgG, IgA, IgM, IgD, trans-
ferrin, fibrinogen, a2-macroglobulin, a1-antitrypsin, haptoglobin,
a1-acid glycoprotein, ceruloplasmin, apolipoprotein A-I,
apolipoprotein A-II, apolipoprotein B, complement C1q, comple-
ment C3, complement C4, plasminogen, and prealbumin). Follow-
ing depletion, we fractionated our samples using the high pH
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reversed-phase “Spider fractionator” into 24 fractions as described
previously (Kulak et al, 2017).
Sample preparation: protein digestion and
in-StageTip purification
Sample preparation was carried out according to our Plasma
Proteome Profiling pipeline as described in Geyer et al (2016a,b) with
an automated setup on an Agilent Bravo Liquid Handling Platform. In
brief, plasma samples were diluted 1:10 with ddH2O and 10 ll of the
sample was mixed with 10 ll PreOmics lysis buffer (P.O. 00001,
PreOmics GmbH) for reduction of disulfide bridges, cysteine alkyla-
tion, and protein denaturation at 95°C for 10 min (Kulak et al, 2014).
Trypsin and LysC were added to the mixture after a 5-min cooling
step at room temperature, at a ratio of 1:100 micrograms of enzyme
to micrograms of protein. Digestion was performed at 37°C for 1 h.
An amount of 20 lg of peptides was loaded on two 14-gauge
StageTip plugs, followed by consecutive purification steps according
to the PreOmics iST protocol (www.preomics.com). The StageTips
were centrifuged using an in-house 3D-printed StageTip centrifugal
device at 1,500 g. The collected material was completely dried using
a SpeedVac centrifuge at 60°C (Eppendorf, Concentrator plus).
Peptides were suspended in buffer A* [2% acetonitrile (v/v), 0.1%
formic acid (v/v)] and sonicated (Branson Ultrasonics, Ultrasonic
Cleaner Model 2510). Pools for each of the five sample types (whole
blood, erythrocytes, platelets, plasma, and platelet-free plasma) were
generated from the 20 individuals and prepared according to the
procedure above. The peptides were fractionated using the high pH
reversed-phase “Spider fractionator” into 24 fractions as described
previously to generate deep proteomes (Kulak et al, 2017).
Ultra-high-pressure liquid chromatography and
mass spectrometry
Samples were measured using LC-MS instrumentation consisting of
an EASY-nLC 1000 or 1200 ultra-high-pressure system (Thermo
Fisher Scientific), which was coupled to a Q Exactive HF Orbitrap
(Thermo Fisher Scientific) using a nano-electrospray ion source
(Thermo Fisher Scientific). Purified peptides were separated on 40-
cm HPLC columns [ID: 75 lm; in-house packed into the tip with
ReproSil-Pur C18-AQ 1.9 lm resin (Dr. Maisch GmbH)]. For each
LC-MS/MS analysis, about 0.5 lg peptides were used for 45-min
runs and for each fraction of the deep plasma data set.
Peptides were loaded in buffer A [0.1% formic acid and 5% DMSO
(v/v)] and eluted with a linear 35-min gradient of 3–30% of buffer B
[0.1% formic acid, 5% DMSO, and 80% (v/v) acetonitrile], followed
stepwise by a 7-min increase to 75% of buffer B and a 1-min increase
to 98% of buffer B, followed by a 2-min wash of 98% buffer B at a
flow rate of 450 nl/min. Column temperature was kept at 60°C by an
in-house-developed oven containing a Peltier element, and parame-
ters were monitored in real time by the SprayQC software (Scheltema
& Mann, 2012). MS data were acquired with a Top15 data-dependent
MS/MS scan method for the construction of the library and BoxCar
scans (Meier et al, 2018) for the study samples. Target values for the
full-scan MS spectra were 3 × 106 charges in the 300–1,650 m/z
range with a maximum injection time of 55 ms and a resolution of
60,000 at m/z 200. Fragmentation of precursor ions was performed
by higher-energy C-trap dissociation (HCD) with a normalized colli-
sion energy of 27 eV. MS/MS scans were performed at a resolution of
30,000 at m/z 200 with an ion target value of 1 × 105 and a maxi-
mum injection time of 120 ms. Dynamic exclusion was set to 30 s to
avoid repeated sequencing of identical peptides.
Data analysis
MS raw files were analyzed by MaxQuant software, version 1.5.6.8,
(Cox & Mann, 2008), and peptide lists were searched against the
human UniProt FASTA database. A contaminant database generated
by the Andromeda search engine (Cox et al, 2011) was configured
with cysteine carbamidomethylation as a fixed modification and N-
terminal acetylation and methionine oxidation as variable modifi-
cations. We set the false discovery rate (FDR) to 0.01 for protein and
peptide levels with a minimum length of 7 amino acids for peptides,
and the FDR was determined by searching a reverse database. Enzyme
specificity was set as C-terminal to arginine and lysine as expected
using trypsin and LysC as proteases. A maximum of two missed cleav-
ages were allowed. Peptide identification was performed with an initial
precursor mass deviation up to 7 ppm and a fragment mass deviation
of 20 ppm. The “match between run algorithm” in the MaxQuant
quantification (Nagaraj et al, 2012) was enabled after constructing a
matching library consistent of depleted and all the undepleted plasma
samples. All proteins and peptides matching to the reversed database
were filtered out. Label-free protein quantitation (LFQ) was performed
with a minimum ratio count of 2 (Cox et al, 2014).
Bioinformatic analysis
All bioinformatic analyses were performed with the Perseus soft-
ware of the MaxQuant computational platform (Cox & Mann, 2008;
The paper explained
Problem
New biomarkers are urgently needed in many health and disease
contexts and mass spectrometry-based proteomics is a potentially
powerful and promising technology for their discovery, as it can
analyze the plasma proteome in a quantitative and specific manner.
However, a systematic analysis of pre-analytical variations might
obscure the discovery of novel biomarkers and has not been
performed so far.
Results
We employ Plasma Proteome Profiling to discover three quality
marker panels that report on the status of plasma samples with
regards to erythrocyte lysis, platelet contamination, and partial coagu-
lation. These panels can identify individual samples of poor quality
and correct for systematic bias in biomarker studies. Moreover, they
can be applied to evaluate whether a novel biomarker candidate is
linked to one of the sources of contamination. We further provide
sample preparation guidelines and an online resource to assess the
overall sample-related bias in individual samples in clinical studies.
Impact
Quality issues due to erythrocyte lysis, platelet contamination, and
partial coagulation might affect up to 50% of all biomarker studies as
we showed by a literature survey of more than 200 published manu-
scripts. Our quality marker panels will prevent costly miss-assignment
of potential biomarker candidates and support the discovery of
promising biomarkers.
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Tyanova et al, 2016). For the global correlation analysis, proteins
were filtered for at least 50% valid values in the weight loss study
and the hierarchical clustering was performed using Euclidean
distance. The weight loss study contained in total 28 proteins of the
platelet panel, but after sorting for 50% valid values only 24 were
left and all of them clustered in the platelet panel.
Online platform for automated analysis of clinical studies
Our online portal is equipped with a user-friendly graphical inter-
face that supports the most common web browsers, such as Google
Chrome, Firefox, and Internet Explorer. For the front-end develop-
ment, a Dash framework was used (version 0.27.0), which consists
of a Flask server (1.0.2) that communicates with front-end React.js
components using JSON, or JavaScript Object Notation, packets (a
minimal, readable format for structuring data) over HTTP, or Hyper-
text Transfer Protocol, requests that work as request–response
protocols between a client and server. Taking advantage of the full
power of Cascading Style Sheets (CSS), every graphical element was
customized: the sizing, the positioning, the colors, and the fonts.
The platform takes the results of the MS data processed by the
MaxQuant software (Cox & Mann, 2008) from the proteinGroups
table (to be extended to other formats). During the data uploading,
the input file is verified through a combination of preliminary tests.
We built a complex data structure using general Python libraries,
such as NumPy, Pandas, and SciPy. Using three panels of markers for
platelet contamination, erythrocyte contamination, and coagulation
events in plasma samples, respectively, we identify samples affected
by quality issues. Samples having at least 50% “valid values” (i.e.
those with quantification results) are preprocessed by cleaning the
data and prepare them for the subsequent visualization step.
Data availability
The MS-based proteomic data have been deposited to the Proteo-
meXchange Consortium via the PRIDE partner repository and are
available via ProteomeXchange with identifier PXD011749 (https://
www.ebi.ac.uk/pride/archive/projects/PXD011749).
Expanded View for this article is available online.
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